Abbvie Inc Stock Price, News & Analysis

AbbVie (NYSE: ABBV) has entered into an exclusive licensing agreement with IGI Therapeutics SA for ISB 2001, a first-in-class CD38×BCMA×CD3 trispecific antibody currently in Phase 1 clinical trials for relapsed/refractory multiple myeloma.

Under the agreement, AbbVie gains exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. IGI will receive an upfront payment of $700 million and is eligible for up to $1.225 billion in milestone payments, plus tiered, double-digit royalties on net sales.

ISB 2001 was developed using IGI's proprietary BEAT® protein platform and represents a new frontier in immuno-oncology by engaging multiple targets simultaneously.

AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash. The acquisition centers on Capstan's lead asset CPTX2309, a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy currently in Phase 1 clinical trials for B cell-mediated autoimmune diseases.

CPTX2309 delivers mRNA encoding an anti-CD19 chimeric antigen receptor to CD8-expressing cytotoxic T cells in vivo, offering a novel approach to treating autoimmune conditions. The therapy aims to deplete autoreactive antibody-producing pathogenic memory B cells and achieve immune system reset without requiring lymphodepletion preconditioning or complex ex vivo manufacturing.

The acquisition also includes Capstan's proprietary tLNP platform technology designed for RNA payload delivery. The transaction is subject to customary closing conditions, including Hart-Scott-Rodino Antitrust Improvements Act requirements.

[ "Acquisition of potential first-in-class therapy CPTX2309 currently in Phase 1 trials", "Technology eliminates need for complex ex vivo manufacturing and lymphodepletion preconditioning", "Platform has potential to treat wide range of autoimmune diseases", "Acquisition includes valuable proprietary tLNP platform technology" ]

AbbVie (NYSE:ABBV) announced that the FDA has accepted for review the supplemental premarket approval (sPMA) application for SKINVIVE by JUVÉDERM® to reduce neck lines and improve neck appearance. The product is currently approved in the U.S. for improving cheek skin smoothness in adults over 21.

The application is supported by a successful clinical study where 80% of patients achieved at least a 1-grade improvement in horizontal neck lines at month 1, and nearly 90% reported improvement in neck appearance. Treatment-emergent adverse events were mild and consistent with the known safety profile.

If approved, SKINVIVE by JUVÉDERM® would become the first hyaluronic acid injectable treatment specifically targeting neck lines, addressing a significant market need as neck appearance is a top concern among aesthetic treatment seekers.

AbbVie (NYSE: ABBV) has scheduled its second-quarter 2025 financial results announcement for Thursday, July 31, 2025, before market opening. The company will host a live earnings conference call at 8 a.m. Central time. Investors can access the webcast through AbbVie's Investor Relations website at investors.abbvie.com, with an archived version available later that day.

AbbVie (NYSE: ABBV) has announced a quarterly cash dividend of $1.64 per share, payable on August 15, 2025, to stockholders of record as of July 15, 2025. The pharmaceutical company has demonstrated strong commitment to shareholder returns, increasing its dividend by 310 percent since its establishment in 2013. AbbVie's consistent dividend growth has earned it a place in the prestigious S&P Dividend Aristocrats Index, which includes companies that have raised their dividends for at least 25 consecutive years.

AbbVie announced positive Phase 3 TEMPLE study results comparing atogepant (QULIPTA/AQUIPTA) to topiramate for migraine prevention. The study demonstrated superior safety and efficacy of atogepant, with significantly fewer treatment discontinuations due to adverse events (12.1% vs 29.6%). Notably, 64.1% of atogepant patients achieved ≥50% reduction in monthly migraine days compared to 39.3% for topiramate. The study met all primary and secondary endpoints, validating CGRP inhibitors as first-line preventive treatment. Atogepant, approved in 60 countries, maintains its established safety profile and offers a promising solution for the 14% of global population affected by migraine, addressing the current gaps in preventive treatment where over 50% of patients still qualify for additional preventive therapy.

AbbVie (ABBV) announced that its Phase 3 VERONA trial, testing venetoclax combined with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS), failed to achieve its primary endpoint of overall survival. The trial showed a hazard ratio of 0.908 with a stratified log-rank p-value of 0.3772, indicating statistical insignificance. While no new safety concerns emerged during the trial, this setback represents a missed opportunity in expanding venetoclax's treatment applications. The company plans to present detailed results at future medical conferences or in publications. Importantly, AbbVie emphasized that these results do not affect venetoclax's currently approved indications.

AbbVie (ABBV) received FDA approval for an expanded indication of MAVYRET, making it the first and only treatment for acute Hepatitis C Virus (HCV). The oral pangenotypic treatment demonstrates a 96% cure rate in just eight weeks for both adult and pediatric patients (3+ years) with acute or chronic HCV. This breakthrough therapy can now be administered immediately upon diagnosis, addressing a critical healthcare need. The approval is supported by Phase 3 study results showing high efficacy with mild to moderate side effects. This development is particularly significant as untreated HCV could lead to severe liver complications, with the US expected to face $120 billion in related medical costs through 2035. The expansion aligns with global clinical guidelines and public health goals to eliminate HCV by 2030, though most high-income countries, including the US, are currently not on track to meet this target until after 2050.

AbbVie (ABBV) has launched the second annual AbbVie Migraine Career Catalyst Award contest, offering $2,500 each to 20 winners to support their professional development goals. The contest, running until September 2, 2025, aims to help people with migraine pursue career advancement despite the condition's workplace challenges. Migraine affects up to 90% of sufferers' work productivity, with most productivity loss occurring while working through symptoms. The initiative builds on last year's success, where 20 winners used funds for creating migraine-friendly workspaces, attending conferences, and pursuing certifications. AbbVie, which offers three approved migraine treatments, demonstrates its commitment to supporting the migraine community beyond medical solutions. Winners will be announced around November 14, 2025, and entries can be submitted via essay, video, or audio format at migrainecareercatalyst.com.